Coherus Biosciences (CHRS) Price & Analysis

Compare

1,606 Followers

CHRS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $2.43

Previous CloseN/A

Volume565.36K

Average Volume (3M)1.34M

Market Cap

$106.45M

Enterprise Value-$98.62M

Total Cash (Recent Filing)$237.64M

Total Debt (Recent Filing)$2.41M

Price to Earnings (P/E)5.5

Beta1.66

Next Earnings

Nov 10, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding116,227,270

10 Day Avg. Volume1,386,365

30 Day Avg. Volume1,339,873

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.93

Enterprise Value/Revenue-0.69

Enterprise Value/Gross Profit-1.22

Enterprise Value/Ebitda0.72

Forecast

1Y Price Target

$3.03

Price Target Upside197.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Market PositionLoqtorzi has restored growth momentum and targets the community setting to drive further expansion, supported by strong uptake following its inclusion in NCCN guidelines.

Product DevelopmentDevelopment of anti-CCR8 mAb CHS-114 and IL-27 antagonist casdozokitug progresses apace, with Coherus owning global rights and seeking ex-US partners.

Strategic ShiftCoherus completed its strategic transition to focus on novel oncology, marked by the sale of its biosimilar business, which extinguished debt and provided funding for future growth.

Bears Say

Financial PerformanceNon-GAAP net loss was worse than forecast, with Q2 showing a loss of $0.34 per share, $0.01 worse than anticipated.

Market CompetitionCheckpoint inhibitors remain a crowded space dominated by large pharma players, and Coherus' pipeline assets are relatively early stage.

Sales PerformanceLoqtorzi sales of $7.6MM in Q1 were slightly below estimates, reflecting little quarter-on-quarter growth.

Coherus Biosciences News

Coherus Biosciences reports Q2 EPS (39c), consensus (27c)

Reports Q2 revenue $10.25M, consensus $9.28M. Cash, cash equivalents and marketable securities totaled $237.6M as of June 30,...

8d ago

CHRS

Coherus Oncology’s Earnings Call Highlights Growth and Challenges

Coherus Biosciences (($CHRS)) has held its Q2 earnings call. Read on for the main highlights of the call....

4d ago

CHRS

Coherus Biosciences: Buy Rating Affirmed Amid Strong Sales Alignment and Promising Pipeline Developments

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on CHRS stock, giving a Buy rating today....

7d ago

CHRS

Coherus Biosciences: Promising Growth and Strategic Positioning Justify Buy Rating

Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on Coherus Biosciences and keeping the price target...

7d ago

CHRS

Coherus Oncology Reports Strong Q2 2025 Growth

Coherus Biosciences ( ($CHRS) ) has released its Q2 earnings. Here is a breakdown of the information Coherus...

8d ago

CHRS

CHRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Coherus Biosciences (CHRS) is scheduled to report 2nd quarter earnings on 07/31/2025. Regarding Q2 estimates, Wall Street analysts...

18d ago

CHRS

Coherus Biosciences Receives Nasdaq Deficiency Notice

An announcement from Coherus Biosciences ( ($CHRS) ) is now available. On June 30, 2025, Coherus Oncology, Inc....

1M ago

CHRS

Coherus Biosciences Holds Virtual Annual Stockholder Meeting

An announcement from Coherus Biosciences ( ($CHRS) ) is now available. On June 11, 2025, Coherus Oncology, Inc....

2M ago

CHRS

Coherus Biosciences Rebrands to Coherus Oncology

Coherus Biosciences ( ($CHRS) ) has provided an update. On May 29, 2025, Coherus BioSciences, Inc. changed its...

3M ago

CHRS

Coherus Biosciences completes transformation to Coherus Oncology

Coherus Oncology formerly named Coherus BioSciences (CHRS), announced its name change to better align with its exclusive focus...

3M ago

CHRS

Coherus Biosciences announces clinical collaboration with STORM Therapeutics

Coherus BioSciences (CHRS) announced a clinical collaboration with STORM Therapeutics to evaluate STC-15, a METTL3 inhibitor, in combination...

3M ago

CHRS

Coherus BioSciences Earnings Call Highlights Transition and Growth

Coherus Biosciences (($CHRS)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

CHRS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

BMY

ABBV

Strategic Divestment and Ambitious Targets Support Coherus Biosciences’ Buy Rating

TD Cowen analyst Michael Nedelcovych has reiterated their bullish stance on CHRS stock, giving a Buy rating yesterday....

3M ago

CHRS

CHRS FAQ

What was Coherus Biosciences’s price range in the past 12 months?

Coherus Biosciences lowest stock price was $0.66 and its highest was $2.43 in the past 12 months.

What is Coherus Biosciences’s market cap?

Coherus Biosciences’s market cap is $106.45M.

When is Coherus Biosciences’s upcoming earnings report date?

Coherus Biosciences’s upcoming earnings report date is Nov 10, 2025 which is in 87 days.

How were Coherus Biosciences’s earnings last quarter?

Coherus Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.17.

Is Coherus Biosciences overvalued?

According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Coherus Biosciences pay dividends?

Coherus Biosciences does not currently pay dividends.

What is Coherus Biosciences’s EPS estimate?

Coherus Biosciences’s EPS estimate is -0.33.

How many shares outstanding does Coherus Biosciences have?

Coherus Biosciences has 116,227,270 shares outstanding.

What happened to Coherus Biosciences’s price movement after its last earnings report?

Coherus Biosciences reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went down -6.818%.

Which hedge fund is a major shareholder of Coherus Biosciences?

Currently, no hedge funds are holding shares in CHRS

Coherus Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-860.65%

Trailing 12-Months

Asset Growth

-34.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Coherus Biosciences

Coherus Biosciences (CHRS) is a biotechnology company focused on developing and commercializing innovative biologic medicines. The company specializes in biosimilars, which are biologic medical products highly similar to already approved reference products, aimed at improving patient access to essential therapies. Coherus operates primarily in the oncology and autoimmune disease sectors, offering a range of products that include both FDA-approved biosimilars and a robust pipeline of candidates in various stages of development.

Coherus Biosciences (CHRS) Earnings & Revenues

Historic Earnings Reports

CHRS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call conveyed a mostly positive outlook for Coherus Oncology, emphasizing strong revenue growth and strategic repositioning success. However, challenges with community adoption and dependency on future data readouts were noted.View all CHRS earnings summaries

CHRS Stock 12 Month Forecast

Average Price Target

$3.03

▲(197.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.03,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,1.3507692307692307,1.8215384615384616,2.292307692307692,2.763076923076923,3.233846153846154,3.7046153846153844,4.1753846153846155,4.6461538461538465,5.116923076923077,5.587692307692308,6.058461538461539,6.529230769230769,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,1.0453846153846154,1.2107692307692308,1.376153846153846,1.5415384615384615,1.706923076923077,1.8723076923076922,2.0376923076923075,2.203076923076923,2.3684615384615384,2.5338461538461536,2.6992307692307693,2.8646153846153846,{"y":3.03,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.8892307692307693,0.8984615384615384,0.9076923076923077,0.916923076923077,0.9261538461538461,0.9353846153846154,0.9446153846153846,0.9538461538461538,0.963076923076923,0.9723076923076923,0.9815384615384615,0.9907692307692307,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.06,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >